Strides Arcolab is currently trading at Rs. 601.50, up by 2.45 points or 0.41% from its previous closing of Rs. 599.05 on the BSE.
The scrip opened at Rs. 605.10 and has touched a high and low of Rs. 612.50 and Rs. 598.50 respectively. So far 26,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 628.50 on 02-Apr-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 628.50 and Rs. 551.00 respectively. The current market cap of the company is Rs. 3,511.00 crore.
The promoters holding in the company stood at 28.42% while Institutions and Non-Institutions held 54.49% and 17.09% respectively.
Strides Arcolab has received approval from Health Canada for Tobramycin Injection USP 40 mg / mL, Liquid dosage form. Tobramycin is in a group of antibiotics called aminoglycosides used to treat bacterial infections of the skin, heart, stomach, brain and spinal cord, respiratory system, and urinary tract. It is also used in the treatment of cystic fibrosis. Tobramycin injection is sometimes used together with other antibiotics.
The approval was granted under the expedited review process being adopted by Health Canada to address the severe drug shortage situation in Canada. In March 2012, Canadian Health Ministry had indicated that Health Canada will approve suppliers within a month to ease the drug shortage in Canada.
The market value of the product is approximately $4.2 million. The product will be commercialized in Q2 of 2012 directly by Strides Canadian subsidiary.
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1811.10 |
| Dr. Reddys Lab | 1344.30 |
| Cipla | 1472.00 |
| Lupin | 2157.80 |
| Zydus Lifesciences | 969.65 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
